Belite Bio (BLTE)
160.62
+7.78 (5.09%)
Upcoming Events
Latest Headlines
Belite Bio reports Phase 3 tinlarebant data at ASRS meeting
July 20, 2026 8:00 AM - StreetInsider
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
July 20, 2026 8:00 AM - StreetInsider
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 15, 2026 8:00 AM - StreetInsider
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 6, 2026 8:00 AM - StreetInsider
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 6, 2026 7:00 AM - StreetInsider
Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter
June 22, 2026 6:06 AM - SEC Filing
Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter
June 18, 2026 4:27 PM - SEC Filing
Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter
June 17, 2026 6:04 AM - SEC Filing
Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter
June 16, 2026 7:11 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
June 16, 2026 6:44 AM - StreetInsider
Form 6-K BELITE BIO, INC For: Jun 12
June 15, 2026 6:15 AM - SEC Filing
Belite Bio completes FDA drug application for rare eye disease treatment
June 15, 2026 3:02 AM - StreetInsider
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026 9:30 PM - StreetInsider
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026 8:00 AM - StreetInsider
Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho
May 26, 2026 5:50 AM - StreetInsider
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
May 22, 2026 9:33 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
May 21, 2026 6:38 AM - StreetInsider
Form 6-K BELITE BIO, INC For: May 20
May 20, 2026 6:04 AM - SEC Filing
Belite Bio (BLTE) Tops Q1 EPS by 30c
May 20, 2026 6:03 AM - StreetInsider
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026 6:00 AM - Globe NewsWire
Belite Bio receives orphan drug status in Switzerland for retinal therapy
May 18, 2026 4:00 PM - StreetInsider
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026 4:00 PM - Globe NewsWire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G/A BELITE BIO, INC Filed by: Lin Yu-Hsin
May 14, 2026 4:00 PM - SEC Filing
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026 4:00 PM - Globe NewsWire
Form 4 BELITE BIO, INC For: May 07 Filed by: MATA NATHAN L.
May 8, 2026 4:46 PM - SEC Filing
Form 4 BELITE BIO, INC For: May 06 Filed by: MATA NATHAN L.
May 7, 2026 4:18 PM - SEC Filing
Form 4 BELITE BIO, INC For: May 05 Filed by: MATA NATHAN L.
May 6, 2026 4:15 PM - SEC Filing
Form 4 BELITE BIO, INC For: May 04 Filed by: MATA NATHAN L.
May 5, 2026 4:16 PM - SEC Filing
Form 4 BELITE BIO, INC For: May 01 Filed by: MATA NATHAN L.
May 4, 2026 4:15 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 30 Filed by: MATA NATHAN L.
May 1, 2026 4:16 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 29 Filed by: MATA NATHAN L.
April 30, 2026 4:19 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 28 Filed by: MATA NATHAN L.
April 29, 2026 4:34 PM - SEC Filing
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026 8:35 AM - Globe NewsWire
Form 4 BELITE BIO, INC For: Apr 27 Filed by: MATA NATHAN L.
April 28, 2026 4:28 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 24 Filed by: MATA NATHAN L.
April 27, 2026 4:52 PM - SEC Filing
Prevent Blindness Declares May as Third Annual Inherited Retinal Disease and Genetic Testing Month, Offering Resources to Public and Healthcare Allies, to Help Save Sight
April 27, 2026 10:15 AM - PR NewsWire
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026 8:00 AM - Globe NewsWire
Form 4 BELITE BIO, INC For: Apr 23 Filed by: MATA NATHAN L.
April 24, 2026 4:15 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 21 Filed by: Lin Yu-Hsin
April 23, 2026 7:10 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 21 Filed by: Scholl Hendrik Peter
April 23, 2026 7:10 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 21 Filed by: Chuang Hao-Yuan
April 23, 2026 7:10 PM - SEC Filing
Form 4 BELITE BIO, INC For: Apr 22 Filed by: MATA NATHAN L.
April 23, 2026 7:10 PM - SEC Filing
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026 8:35 AM - Globe NewsWire
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026 8:01 AM - Globe NewsWire
Form 4 BELITE BIO, INC For: Apr 21 Filed by: MATA NATHAN L.
April 22, 2026 4:16 PM - SEC Filing
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026 8:35 AM - Globe NewsWire
Full Article List
